Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

Leukemia

Volumn 22, Issue 1, 2008, Pages 147-160

  Papa, V ^a   Tazzari, P L ^b   Chiarini, F ^a   Cappellini, A ^c   Ricci, F ^b   Billi, A M ^a   Evangelisti, C ^a   Ottaviani, E ^a   Martinelli, G ^a   Testoni, N ^a   McCubrey, J A ^d   Martelli, A M ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

^e CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD135 ANTIGEN; CD34 ANTIGEN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 38349074064     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404980     Document Type: Article

References (60)

1. Okamoto T, Sanda T, Asamitsu K. NF-κ B signaling and carcinogenesis. Curr Pharm Design 2007; 13: 447-462.
2. Pardee AB. Tumor progression - targets for differential therapy. J Cell Physiol 2006; 209: 589-591.
3. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002; 21: 1263-1271.
4. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5: 234-248.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-901.
6. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464.
7. Hanada M, Feng J, Hemmings BA. Structure, regulation ind function of PKB/ AKT - a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16.
8. Recher C, Pos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4: 1540-1549.
9. Cheng JQ, Lindsley CW, Cheng-GZ, Yang H, Nicosia SV. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 2005; 24: 7482-7492.
10. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4 988-1004.
11. Levis M. Recent advances in the development of smalt-molecule inhibitors for the treatment of acute myeloid leukemia. Curr Opin Hematol 2005; 12: 55-61.
12. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4: 257-262.
13. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S et al. Phase I and pharmacological study of daily-oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002; 38: 1615-1621.
14. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004; 10: 7450-7456.
15. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062.
16. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14 167-173.
17. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
18. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005; 65: 7429-7435.
19. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689.
20. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18: 103-112.
21. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586-594.
22. Matkovic K, Brugnoli F, Bertagnolo V, Banfic H, Visnjic D. The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia 2006; 20: 941-951.
23. Martelli AM, Nyakem M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928.
24. Komblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365.
25. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007; 21: 1921-1930.
26. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T et al Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndromo patients. Leukemia 2006; 20: 230-238.
27. Rahmani M, Feese E, Dai Y, Bauer C, Payne SG, Dent P et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422-2432,
28. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509-3512.
29. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427-438.
30. Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K et al. Quantitation of Fas and Fas ligand gene expression in human ovarian cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000; 82: 1682-1688,
31. Zamai L, Canonico B, Luchetti F, Ferri P, Melloni E, Guidotti L et al Supravital exposure to propidium iodide identifies apoptosis on adherent cells. Cytometry 2001; 44: 57-64.
32. Hail Jr N, Carter BZ, Konopleva M, Andreeff M. Apoptogis effector mechanisms: A requiem performed in different keys. Apoptosis 2006; 11: 889-904.
33. Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: Identification of five sites of phosphorylation in vivo. Biochem J 1999; 342: 267-292.
34. Nyakern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006; 5: 1559-1570.
35. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemminge BA et al p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J. Biol Chem 2000; 275: 41201-41209.
36. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M et al Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apcotosis in myeloid leukemias. Leukemia 2004; 18: 267-275.
37. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and P13K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8: 287-297.
38. Lee SY, Cherla RP, Tesh VL. Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect Immun 2007; 75: 1291-1302.
39. Kappelmayer J, Udvardy-M, Antal-Szalmas P. Pgp and FLT3: Identification and modulation of two proteins that lead to chemotherapy resistance in acute myeloid leukemia. Curr Med Chem 2007; 14: 519-530.
40. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3-feceptor tyrosine kinase. Blood 2002; 100: 2941-2949.
41. Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev 2007; 33: 191-202.
42. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R et al A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006; 5: 766-770.
43. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG et al A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2007 (in press).
44. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E et al. Quantitative single tell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005; 19: 1543-1549.
45. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 2003; 17: 1783-1793.
46. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B et al. A selectve inhibitor of the p110§ isoform of Pl 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006; 25: 6648-6659.
47. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in RTEN-deficieht cancer cells. Oncogene 2006; 25 525-535.
48. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistante. Biochim Biophys Acta 2007; 1773: 1263-1284.
49. Advani AS. PLT3 and acute myelogenous leukemia biology, clinical significante and therapeutic applications. Curr Pharm Des 2005; 11: 3449-3457.
50. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
51. Ciechomska I, Pyrzynska B, Kazmierczak P, Kaminska B. Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene 2003; 22: 7617-7627.
52. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM et al. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 2003; 17: 2157-2167.
53. Gross A. BID as a double agent in cell life and death. Cell Cycle 2006; 5: 582-584.
54. Droin N, Bichat F, Rebe C, Wotawa A, Sordet O, Hammann A et al. Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood 2001; 97: 1835-1844.
55. Wagner KW, Engels IH, Deveraux QL. Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem 2004; 279: 35047-35052.
56. Prasad V, Chandele A, Jagtap JC, Sudheer Kumar P, Shastry P. ROS-triggered caspase 2 activation and feedback amplification loop in betacarotene-induced apoptosis. Free Radic Biol Med 2006; 41 431-442.
57. Barthelemy C, Henderson CE, Pettmann B. Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci 2004; 5: 48.
58. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-420.
59. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS et al. Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002; 22 7831-7841.
60. Shtivelman E, Sussman J, Stokoe D. A role for Pl 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 2002; 12: 919-924.